Carl LeBel, Ph.D.
Chief Development Officer, Frequency Therapeutics
Carl LeBel, Ph.D., has been the Chief Development Officer at Frequency Therapeutics since 2018. He started LeBel Consulting LLC after serving as the Chief Scientific Officer at Otonomy, Inc., from 2009 to 2016. Before joining Otonomy, he was President and CEO of Akesis Pharmaceuticals, Inc., a virtual metabolic disorders company, and prior to that spent more than 14 years at Amgen as an executive director in a variety of R&D management positions. Carl is a scientific fellow of the American Academy of Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Carl is also a co-inventor on numerous patents in the field of drug delivery for otology-related disorders.